Beligas PharmaAOD9604 2 mg
| Quantity | Discount | Price |
|---|---|---|
| 3–5 | 10% | $63,00 |
| 6–9 | 15% | $59,50 |
| 10–100 | 20% | $56,00 |
Specifications
- Brand: Beligas Pharma HGH, Peptides & SARMs
- Substance: AOD9604
- Product Form: Powder
- Dosage: 2 mg
How To Use
Laboratory Reconstitution & Research Dosing Protocols
Disclaimer: The following information is for educational and laboratory reference only. This product is strictly for in-vitro and in-vivo research and is not intended for human consumption or therapeutic use.
This vial contains 2mg (2,000mcg) of lyophilized AOD-9604 powder. Accurate reconstitution is required for precise analytical testing.
Reconstitution Guide
For a standard, easily measurable research concentration, reconstitute the 2mg vial with 2 ml of Bacteriostatic Water.
- Preparation: Slowly inject the 2 ml of water against the glass wall of the vial.
- Dissolution: Swirl the vial gently until the solution is completely clear. Do not shake.
- Measurement Reference: Using a standard U-100 insulin syringe, 10 Units (0.10 ml) equals exactly 100mcg of AOD-9604.
Storage Specifications
- Unmixed (Lyophilized): Store at room temperature away from UV light during transport. For long-term preservation, store at -20°C.
- Mixed (Reconstituted): Must be refrigerated (2°C to 8°C). The peptide bonds remain chemically stable for analytical use for approximately 21 to 30 days.
Experience Level Usage Guide
Beginner
Protocol A: Baseline Lipolysis & Metabolic Observation
Reference dosing for initial subject acclimation and baseline fat oxidation studies.
- Test Subject Dosage: 250mcg daily.
- Administration: Subcutaneous. Administered strictly in a fasted state to prevent insulin from blunting the lipolytic response.
- Observation Period: 20 to 30 days.
Intermediate
Protocol B: Accelerated Adipose Reduction Model
Standard clinical dosage for evaluating rapid shifts in body composition and lipid mobilization.
- Test Subject Dosage: 500mcg daily.
- Administration: Subcutaneous. Split into two 250mcg doses (e.g., morning fasted, and pre-exercise or pre-sleep fasted).
- Observation Period: 4 to 8 weeks.
Advanced
Protocol C: Articular Cartilage & Joint Repair Model
Advanced protocol for research involving connective tissue regeneration in osteoarthritic models.
- Test Subject Dosage: 300mcg to 500mcg daily.
- Administration: Intra-articular (directly into the joint space) or localized subcutaneous administration.
- Synergy: Frequently researched in conjunction with BPC-157 to observe synergistic cartilage matrix repair.
Shipping Details
Detailed Description
What Is Beligas Pharma AOD-9604 2 mg?
Beligas Pharma AOD-9604 2 mg is a synthetic peptide fragment derived from the C-terminus of the human growth hormone (hGH) molecule. Specifically, it encompasses amino acids 177-191 with an additional tyrosine at the N-terminal end. Unlike full-spectrum growth hormone, AOD-9604 is engineered strictly to investigate lipolytic (fat-burning) pathways without impacting blood glucose levels or IGF-1 production.
This 2 mg lyophilized vial by Beligas Pharma provides researchers with a highly purified tool for conducting precise in vitro and in vivo assays focused on metabolic regulation and adipose tissue reduction.
Please note: This product is strictly for laboratory research purposes and is not intended for human consumption or medical use.
| Technical Specification | Details |
|---|---|
| Compound Name | AOD-9604 (Anti-Obesity Drug) |
| Format | 2 mg Lyophilized Powder |
| Purity Level | >99% (HPLC & MS Verified) |
| Primary Research Area | Lipolysis & Metabolic Signaling |
Observed Benefits of AOD-9604 in Research Models
In controlled metabolic research, AOD-9604 has shown unique characteristics compared to traditional growth factors. Key experimental observations include:
- Targeted Lipolysis: Stimulates the breakdown of lipids (fats) by mimicking the way natural hGH regulates fat metabolism in animal models.
- Inhibition of Lipogenesis: Studies indicate a significant reduction in the formation of new fatty acids and triglycerides in adipose tissues.
- Non-Glycemic Response: Research shows no adverse impact on insulin sensitivity or blood sugar levels, differentiating it from full-length HGH.
- Connective Tissue Support: Recent studies explore its potential in promoting chondrocyte repair and improving symptoms in osteoarthritis models.
Mechanism of Action
AOD-9604 works by activating the beta-3 adrenergic receptors in the adipose tissue. Once bound, it initiates a metabolic cascade that triggers the release of fat from cells while simultaneously preventing the storage of new fat. Because the peptide fragment excludes the portion of the HGH molecule responsible for growth and insulin antagonism, it operates purely as a metabolic signaling agent without the systemic side effects of growth hormone.
Comparison: Metabolic & Fat Loss Research Peptides
| Research Peptide | Primary Focus | Comparison to AOD-9604 |
|---|---|---|
| HGH Frag 176-191 | Fat Oxidation | AOD-9604 is an enhanced version of Fragment 176-191 with a tyrosine modification for better stability and bioavailability. |
| Semaglutide | Appetite Suppression | Semaglutide works via the GLP-1 receptor for satiety; AOD-9604 directly targets the adipose tissue for lipolysis. |
| AOD-9604 | Direct Lipolysis | The premier choice for studying fat metabolism without interfering with the growth axis or insulin levels. |
Research Preparation & Storage Protocols
The 2 mg lyophilized powder should be reconstituted with bacteriostatic water before experimental introduction.
- Storage (Unmixed): Vials must be stored frozen (-20°C) for long-term stability and protection against degradation.
- Storage (Reconstituted): Once mixed, the liquid solution should be kept in a laboratory refrigerator (2°C to 8°C) and utilized within 30 days.
Potential Side Effects in Toxicology Studies
Toxicological assessments in research models show that AOD-9604 has a very high safety profile. Because it does not interact with the IGF-1 or insulin receptors, it does not cause the common side effects associated with HGH, such as water retention or glucose intolerance. Minor localized irritation at the site of administration has been occasionally noted in test subjects.
Where to Buy Beligas Pharma AOD-9604 2 mg Online
When conducting critical metabolic assays, the purity and batch consistency of your compounds are paramount. Peptidesline supplies laboratory-grade Beligas Pharma AOD-9604 2 mg, verified for 100% purity and structural integrity.
- Rapid US Logistics: Shipped directly from our USA facility, ensuring delivery in 4-7 business days.
- Secure Transactions: Checkout seamlessly with Zelle or Venmo for laboratory privacy.
- Crypto Discount: Unlock an instant 10% discount on your entire order by paying with Bitcoin, Ethereum, USDT or Litecoin.
- Click here for Payment Options
FAQ
AOD-9604 only includes the fat-burning (lipolytic) fragment of HGH. It lacks the sections of the molecule that stimulate growth and interfere with insulin, making it a targeted metabolic research tool.
For a 2 mg (2,000 mcg) vial, adding 2 ml of bacteriostatic water is the standard protocol at Peptidesline.com. On this peptide scale, 10 units on an insulin syringe equals 100 mcg. This 1:1 ratio is ideal for researchers who need to measure precise doses between 250 mcg and 500 mcg to assess fat metabolism.
Yes, AOD-9604 is currently being studied for its potential regenerative effects on cartilage and its ability to improve symptoms in osteoarthritis models.
Yes. At Peptidesline.com, we highlight that AOD9604 is most effective in a fasted state. Insulin can interfere with the peptide's ability to signal fat cells to break down. For optimal research results, it should be administered on an empty stomach, typically in the morning or several hours after the last meal of the day.
Once mixed with bacteriostatic water, the peptide is stable for about 30 days when kept in a controlled refrigerator environment at 2-8°C.
While metabolic changes begin immediately, visible body fat reduction typically becomes apparent after 4 to 6 weeks of consistent daily use combined with a calorie-controlled diet.
No. Unlike full-sequence Somatropin, AOD-9604 does not interact with the receptors responsible for cellular hyperplasia or IGF-1 secretion. Its effects are strictly limited to metabolic regulation and fat oxidation, preventing unwanted growth side effects in non-target tissues.
